FDA's Pazdur: I Won't Turn Into A Bureaucrat; My Presence Will Be Felt
Executive Summary
Richard Pazdur, who is moving from being the head of the FDA's Office of Hematology and Oncology Products (OHOP) to the agency's acting director of the newly created Oncology Center of Excellence, established under the White House's National Cancer Moonshot initiative, sat down with reporters on June 29 to explain his new role, but warned don't think he's just going to turn into some sort of a bureaucrat and to anticipate his presence to continue to very much be felt at OHOP.
You may also be interested in...
FDA's Pazdur Jumps Over To New 'Moonshot' Role
Richard Pazdur has been tapped to run the FDA's new Oncology Center of Excellence, which is being created under the White House's National Cancer Moonshot initiative. That means Pazdur, who has been at the FDA since 1999, will be setting aside his duties, for the time being, running the Office of Hematology and Oncology Products – leaving that job in the interim to someone else.
Unifying On Immunotherapy: Will It Pay Off?
It's too early to know now whether the $250m billionaire tech entrepreneur Sean Parker is pumping into immunotherapy will pay off.
Can 'Moon Shot' Lift FDA Out Of Its Silos?
Even though the White House's "moon shot" initiative is focused on cancer, a key component of the program – a new multimillion-dollar FDA "virtual" center for excellence intended to expedite the development and regulatory review of new combination therapies – may be the force to lift the agency out of its silos so that drugs, devices and diagnostics intended to be used together for other types of diseases are not forced to undergo time-consuming separate assessments, said Ellen Sigal, founder and chair of the advocacy group Friends of Cancer Research (FOCR).